A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: A gynecologic oncology group study

作者：Moore David H^*; Ali Shamshad; Koh Wui Jin; Michael Helen; Barnes Mack N; McCourt Carolyn K; Homesley Howard D; Walker Joan L

来源：Gynecologic Oncology, 2012, 124(3): 529-533.

DOI：10.1016/j.ygyno.2011.11.003

• Vulva cancer
• Radiation therapy
• Chemotherapy
• Surgery

Objectives. To determine the efficacy and toxicity of radiation therapy and concurrent weekly cisplatin chemotherapy in achieving a complete clinical and pathologic response when used for the primary treatment of locally-advanced vulvar carcinoma. %26lt;br%26gt;Methods. Patients with locally-advanced (T3 or T4 tumors not amenable to surgical resection via radical vulvectomy), previously untreated squamous cell carcinoma of the vulva were treated with radiation (1.8 Gy daily x 32 fractions = 57.6 Gy) plus weekly cisplatin (40 mg/m(2)) followed by surgical resection of residual tumor (or biopsy to confirm complete clinical response). Management of the groin lymph nodes was standardized and was not a statistical endpoint. Primary endpoints were complete clinical and pathologic response rates of the primary vulvar tumor. %26lt;br%26gt;Results. A planned interim analysis indicated sufficient activity to reopen the study to a second stage of accrual. Among 58 evaluable patients, there were 40 (69%) who completed study treatment. Reasons for prematurely discontinuing treatment included: patient refusal (N=4), toxicity (N=9), death (N=2), other (N= 3). There were 37 patients with a complete clinical response (37/58: 64%). Among these women there were 34 who underwent surgical biopsy and 29 (78%) who also had a complete pathological response. Common adverse effects included leukopenia, pain, radiation dermatitis, pain, or metabolic changes. %26lt;br%26gt;Conclusions. This combination of radiation therapy plus weekly cisplatin successfully yielded high complete clinical and pathologic response rates with acceptable toxicity.

• 出版日期2012-3